UiPath, Inc. Class A Common Stock (PATH)
10.45
+0.07 (0.67%)
NYSE · Last Trade: Apr 19th, 7:31 PM EDT
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at SoundHound AI (NASDAQ:SOUN) and the best and worst performers in the automation software industry.
Via StockStory · April 18, 2025
3 Monster Stocks to Hold for the Next 10 Yearsfool.com
Via The Motley Fool · April 16, 2025
On April 11th, 2025, Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.
Via Benzinga · April 11, 2025
Let’s dig into the relative performance of Jamf (NASDAQ:JAMF) and its peers as we unravel the now-completed Q4 automation software earnings season.
Via StockStory · April 10, 2025
UiPath shares rise on launch of generative AI-based UiPath Medical Record Summarization agent at Google Cloud Next 2025.
Via Benzinga · April 9, 2025
Rock-bottom prices don't always mean rock-bottom businesses.
The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?
Via StockStory · April 9, 2025
Via Benzinga · April 4, 2025
On Thursday, April 3, 2025, Cathie Wood-led Ark Invest purchased Robinhood stock worth $1.39 million amid a broader market slump.
Via Benzinga · April 3, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the automation software industry, including Appian (NASDAQ:APPN) and its peers.
Via StockStory · April 1, 2025
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Dropbox (NASDAQ:DBX) and the rest of the productivity software stocks fared in Q4.
Via StockStory · March 28, 2025
Via The Motley Fool · March 26, 2025
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Microsoft (NASDAQ:MSFT) and the rest of the automation software stocks fared in Q4.
Via StockStory · March 24, 2025
Will the next phase of AI innovation drive this stock to new levels?
Via The Motley Fool · March 22, 2025
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the productivity software industry, including DocuSign (NASDAQ:DOCU) and its peers.
Via StockStory · March 20, 2025
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the automation software stocks, including ServiceNow (NYSE:NOW) and its peers.
Via StockStory · March 19, 2025
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the automation software industry, including Pegasystems (NASDAQ:PEGA) and its peers.
Via StockStory · March 18, 2025
Via The Motley Fool · March 17, 2025
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of March 10-14, 2025.
Via Talk Markets · March 15, 2025
Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox, Repare Therapeutics, and CareDx.
Via Benzinga · March 15, 2025
Via Benzinga · March 14, 2025
Amid the market downturn, the tech stocks that attracted appreciable message volume were mostly the ones that plunged on catalytic events.
Via Stocktwits · March 14, 2025
UiPath, Inc. (NYSE: PATH) shares are trading lower Thursday after the company reported fourth-quarter revenue and issued lower-than-expected revenue guidance for the first quarter.
Via Benzinga · March 13, 2025
UiPath Inc (NYSE: PATH) stock declined on weak Q4 revenue and Q1 guidance. Needham analyst reiterated Hold. Deal delays and uncertainty in US Fed segment.
Via Benzinga · March 13, 2025
UiPath's Q4 results show margin improvements, but analyst cautions on AI transition and growth pressure, lowering price target to $12.
Via Benzinga · March 13, 2025